Lincomycin Injectable (Iv/Im) Suppliers & Bulk Manufacturers
Available Forms: Injectable (IV/IM)
Available Strengths: 600 mg/2 mL, 1 g/2 mL, 2 g/2 mL
Reference Brands: Lincocin (US & EU)
Category:
Antibiotics
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, causing bacterial cell death. It is effective against serious Gram-positive infections, including skin and bone abscesses. Benefits include rapid bacterial eradication, high efficacy against resistant strains, and suitability for severe infections when administered properly in hospital settings.
Lincomycin Injectable (IV/IM) is available in Injectable (IV/IM)
and strengths such as 600 mg/2 mL, 1 g/2 mL, 2 g/2 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lincomycin Injectable (IV/IM) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lincomycin Injectable (IV/IM) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lincomycin injectable is approved in the EU and US for severe bacterial infections, including skin, soft tissue, and bone infections. In the EU, brands like Lincocin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic options are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert regulatory support, dossier preparation, and compliance, visit PharmaTradz. We support seamless market access for lincomycin injectable formulations, adhering to European and US standards for safe, effective antimicrobial therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing